Health Care/Hospital Global News & Press Release Distribution

Health Care/Hospital

All
APAC

2024 ASCO | Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor

SHANGHAI, April 25, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, announced that the Phase I/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 for multiple advanced solid tumors will be presented in an ...

2024-04-25 22:00 417

Hyundai Bioscience's antiviral for Dengue Fever to enter clinical trials in Brazil

* "Aiming to offer a Dengue antiviral treatment course in $100 price range" * Hyundai Bioscience decides to conduct dengue clinical trials in Brazil, which has the largest number of Dengue patients and offers a fast-track approval SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Hyundai Biosc...

2024-04-25 21:41 471

On-Device AI Healthcare Company Noul Announces 2 Clinical Performance Studies at Pan-African Malaria Conference

* miLab showed almost equivalent to WHO-certified first-degree microscopy experts: Sensitivity of 94.4%, Specificity of 98.1% * African authority on malaria diagnosis said "miLab is a potential game changer in accelerating access to parasitological confirmation" YONGIN, South Korea, April 25,...

2024-04-25 21:00 564

On-Device AI Healthcare Company Noul Announces 2 Clinical Performance Studies at Pan-African Malaria Conference

Waterdrop Files Annual Report on Form 20-F for Fiscal Year 2023

BEIJING, April 25, 2024 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it filed its annual report on Form 20-F for the fiscal year ende...

2024-04-25 18:45 578

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

* The only solution for intractable cancer caused by mutations in the p53 gene * Planning clinical trials targeting cancer patients with no available treatment due to p53 gene mutations SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Hyundai Bioscience announced onApril 25th that its clinica...

2024-04-25 17:11 672

PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono

PRISM BioLab will utilize PepMetics®, innovative small molecules that mimic three-dimensional structures of alpha-helix and beta-turns of peptidesfor drug discoveryagainst oncology target selected by Ono TOKYO, April 25, 2024 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery ...

2024-04-25 14:00 548

ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST

SUZHOU, China and ROCKVILLE, Md., April 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from four clinical studies of the co...

2024-04-25 09:02 799

GenScript Biotech Releases 2023 ESG Report: Deepening Green Development Practices, Constructing Sustainable Future Blueprint

PISCATAWAY, N.J., April 24, 2024 /PRNewswire/ -- Recently, GenScript Biotech Corporation (HK.1548), a world leader in technologies and services for life science R&D and manufacture, released its 2023 Environmental, Social, and Governance (ESG) report. This report showcases the company's dedicated...

2024-04-24 22:31 1214

Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting

Topline results from Dizal's global pivotal phase II WU-KONG1 Part B study of sunvozertinib will be showcased in a featured oral presentation at the conference. SHANGHAI, April 24, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new med...

2024-04-24 22:10 941

Future Health highlights greater access to treatment for Mental Health Month

SAN FRANCISCO, April 24, 2024 /PRNewswire/ -- A recent poll has highlighted an alarming trend: a staggering 90% of Americans feel we are in a mental health crisis. While Mental Health Month in May seeks to build ...

2024-04-24 22:00 714

Future Health highlights greater access to treatment for Mental Health Month

Meihua International Medical Technologies Co., Ltd. Reports 2023 Financial Year Results

YANGZHOU, China, April 24, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries inChina, today reported its financial ...

2024-04-24 19:00 1079

Samsung Biologics Reports First Quarter 2024 Financial Results

* Recorded Q1'24 consolidated revenue of KRW 946.9 billion * Recorded Q1'24 consolidated operating profit of KRW 221.3 billion * Sustained growth driven by ongoing strategic expansion in capacity and portfolio INCHEON, South Korea, April 24, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 20794...

2024-04-24 14:45 855

Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab)

Hanmi Pharmaceutical announces Clinical Trial Collaboration with MSD to evaluate 'BH3120' in combination with KEYTRUDA in phase 1 clinical trial in patients with progressive or metastatic solid tumors SEOUL, South Korea, April 23, 2024 /PRNewswire/ -- Hanmi Pharmaceutical (KOSPI: 128940, CEO:Jae...

2024-04-24 09:27 781

Yeast Fuel, Developed by Chula's Faculty of Science Soon to Expand Its Production for the Aerospace Industry

Researchers from Chulalongkorn University have made use of forage grass to feed microorganisms and convert the resulting fat into jet fuel. They aim to expand petroleum-based oil replacement production to reduce impacts on human health and the environment. BANGKOK, ...

2024-04-24 00:00 1090

Yeast Fuel, Developed by Chula's Faculty of Science Soon to Expand Its Production for the Aerospace Industry

STUDIO PILATES INTERNATIONAL ANNOUNCES 100TH STUDIO, WITH CONTINUED EXPANSION AND MILESTONE OPENING

NEW YORK, April 23, 2024 /PRNewswire/ -- Studio Pilates International , has just announced their continued expansion with their100th studio worldwide, and their 7th US opening in Chanhassen, Minnesota

2024-04-23 21:00 769

Zepp Health Corporation Files 2023 Annual Report on Form 20-F

MILPITAS, Calif., April 23, 2024 /PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company") (NYSE: ZEPP) today announced that it has filed its annual report on Form 20-F for the full year endedDecember 31, 2023 with the U.S. Securities and Exchange Commission (the "SEC"). The annual repor...

2024-04-23 20:20 901

OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market

SEOUL, South Korea, April 23, 2024 /PRNewswire/ -- OSR Holdings, a global healthcare holding company, announced that it has signed a memorandum of understanding (MOU) with SillaJen, a Kosdaq-listed biotech firm with a pipeline of immuno-oncology drug candidates, to share technology and clinical ...

2024-04-23 18:37 1171

HanxBio announces the publication of a research paper in Scientific Reports on preclinical evaluation of Narazaciclib for the treatment of acute myeloid leukemia (AML)

SAN DIEGO and WUHAN, China, April 23, 2024 /PRNewswire/ -- HanxBio today announced that it has published a research article titled "Narazaciclib, a novel multikinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models" in the N...

2024-04-23 14:54 879

Brise Pharmaceuticals Raises nearly $20M in Series Pre-A and Pre-A+ Financing

SHANGHAI, April 22, 2024 /PRNewswire/ -- Brise Pharmaceuticals Co., LTD. (Brise), a pioneering company specializing in innovative treatments for acute and chronic pain, has recently completed Pre-A and Pre-A+ financing with a total of approximately$20 million. This Pre-A round is led by Shunxi F...

2024-04-23 08:00 880

PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024

* Preclinical data from the next generation eyedrop platform to be unveiled for the first time at ARVO 2024 DAEJEON, South Korea, April 22, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing next generation therap...

2024-04-23 07:25 1367

12 3 4 5 ... 254